| Literature DB >> 35547881 |
Xiaomin Wang1,2, Yukun Yang3, Min Zhang2.
Abstract
Two self-made aged garlic extract (AGE) were prepared and they were subjected with d-galactose-induced mice to explore vivo antioxidant effects and its mechanism via gene chip analysis. The biochemical analysis results indicated that AGE could significantly reduce the malondialdehyde (MDA) and lipofuscin content and increase the total superoxide dismutase (T-SOD), glutathione peroxidase (GSH-Px), catalase (CAT) activity. Histopathological observations found that AGE could improve the size, shape and arrangement state of liver and brain cells. Furthermore, gene expression profile array was used to screen 35 and 13 differentially expressed genes in liver and brain, respectively. Further analysis showed that the AGE could protect the mice from d-galactose-caused injury via carbohydrate metabolism, immunomodulatory, lipid metabolism, cell cycle regulation, amino acid metabolism and nervous regulation pathways. Through this experiment, we could comprehensively study the antioxidant mechanism of AGE and link the antioxidant function of AGE to the metabolic pathways. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35547881 PMCID: PMC9087883 DOI: 10.1039/c8ra10308a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Effects of AGE on the content of MDA and lipofuscin in liver, brain of d-galactose-induced mice (mean ± SD, n = 12)a
| Groups | MDA | Lipofuscin | ||
|---|---|---|---|---|
| Brain (nmol mg−1 pro) | Liver (nmol mg−1 pro) | Brain (ng g−1) | Liver (ng g−1) | |
| N | 3.35 ± 0.12 | 2.47 ± 0.11 | 41.12 ± 1.65 | 35.63 ± 3.29 |
| C | 6.69 ± 0.44## | 2.78 ± 0.16## | 49.08 ± 1.73## | 57.16 ± 4.99## |
| L-1 | 3.96 ± 0.15** | 2.57 ± 0.08 | 50.53 ± 3.44 | 58.80 ± 3.77 |
| M-1 | 5.69 ± 1.09 | 2.58 ± 0.11 | 42.47 ± 3.08* | 57.69 ± 5.97 |
| H-1 | 4.70 ± 1.12** | 1.02 ± 0.03** | 37.50 ± 3.27** | 45.27 ± 3.14** |
| L-2 | 4.46 ± 0.60** | 2.19 ± 0.07** | 47.31 ± 3.41 | 57.40 ± 2.14 |
| M-2 | 2.79 ± 0.23** | 2.10 ± 0.20** | 49.23 ± 3.45 | 56.85 ± 4.57 |
| H-2 | 3.69 ± 0.11** | 2.24 ± 0.15** | 36.56 ± 5.10** | 43.95 ± 3.54** |
Compared with N group, #P < 0.05, ##P < 0.01; compared with C group, *P < 0.05, **P < 0.01.
Effects of AGE on the activities of CAT, GSH-Px, T-SOD in serum, liver, brain of d-galactose-induced mice (mean ± SD, n = 12)a
| Groups | CAT | GSH-Px | T-SOD | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Serum (U mL−1) | Brain (U mg−1 pro) | Liver (U mg−1 pro) | Serum (U mL−1) | Brain (U mg−1 pro) | Liver (U mg−1 pro) | Serum (U mL−1) | Brain (U mg−1 pro) | Liver (U mg−1 pro) | |
| N | 6.97 ± 0.35 | 108.11 ± 12.18 | 21.03 ± 1.40 | 308.63 ± 26.95 | 602.48 ± 21.98 | 1774.53 ± 121.50 | 88.75 ± 5.42 | 93.62 ± 5.51 | 101.26 ± 11.90 |
| C | 4.63 ± 0.65## | 93.73 ± 6.56# | 14.95 ± 0.28## | 254.95 ± 20.54## | 501.26 ± 14.45# | 1442.84 ± 65.93## | 68.84 ± 1.22## | 67.17 ± 3.02## | 80.76 ± 10.95## |
| L-1 | 4.84 ± 0.35 | 109.52 ± 9.39* | 19.56 ± 0.72** | 268.32 ± 18.16 | 514.82 ± 19.00 | 1447.48 ± 54.76 | 73.37 ± 2.53 | 74.15 ± 8.00 | 89.23 ± 5.83 |
| M-1 | 6.25 ± 0.43** | 131.65 ± 5.34** | 28.28 ± 1.24** | 316.00 ± 18.33** | 599.67 ± 77.69* | 1570.70 ± 30.29* | 72.15 ± 8.10 | 85.80 ± 9.81* | 87.78 ± 8.75 |
| H-1 | 7.00 ± 0.56** | 124.77 ± 5.23** | 27.42 ± 1.65** | 339.47 ± 20.84** | 634.71 ± 68.29** | 1722.30 ± 107.19** | 71.48 ± 3.55 | 92.00 ± 15.57** | 101.18 ± 8.59** |
| L-2 | 4.76 ± 0.48 | 117.67 ± 5.68** | 15.59 ± 3.13 | 264.10 ± 17.45 | 508.22 ± 36.52 | 1542.42 ± 45.30 | 76.05 ± 5.79 | 82.43 ± 8.06 | 90.54 ± 9.13 |
| M-2 | 6.20 ± 0.56** | 127.20 ± 10.44** | 15.44 ± 1.19 | 292.63 ± 21.98* | 489.42 ± 47.15 | 1588.14 ± 51.79* | 83.03 ± 5.76** | 86.49 ± 11.51* | 102.21 ± 6.36** |
| H-2 | 6.78 ± 1.08** | 100.34 ± 4.94 | 26.28 ± 1.29** | 307.79 ± 14.23** | 520.54 ± 13.62 | 1441.39 ± 42.48 | 94.06 ± 5.63** | 83.62 ± 6.84* | 99.23 ± 3.99* |
Compared with N group, #P < 0.05, ##P < 0.01; compared with C group, *P < 0.05, **P < 0.01.
Fig. 1Histopathological analysis of liver. All pictures were taken at 200 times. The letters (A–H) among the figure represent in proper order following groups. N, C, L-1, M-1, H-1, L-2, M-2, and H-2 groups.
Fig. 2Histopathological analysis of brain. All pictures were taken at 200 times. The letters (A–H) among the figure represent in proper order following groups, N, C, L-1, M-1, H-1, L-2, M-2, and H-2 groups.
Co-expression of down-regulated genes and up-regulated genes in liver tissues
| Down-regulated genes | Up-regulated genes | ||||
|---|---|---|---|---|---|
| Gene ID | Gene symbol | Related pathways | Gene ID | Gene symbol | Related pathways |
| 20617 |
| Alzheimer disease; Parkinson disease | 11677 |
| Pentose and glucuronate interconversions; fructose and mannose metabolism; galactose metabolism; glycerolipid metabolism |
| 21356 |
| Antigen processing and presentation | 212647 |
| Alanine, aspartate and glutamate metabolism; arginine and proline metabolism |
| 13122 |
| Primary bile acid biosynthesis; PPAR signaling pathway; steroid hormone synthesis; bile secretion | 13190 |
| Tyrosine metabolism |
| 23882 |
| p53 signaling pathway; cell cycle pathway; MAPK signaling pathway; FoxO signaling pathway | 15139 |
| Complement and coagulation cascades; prion disease; staphylococcus aureus infection; Herpes simplex infection; systemic lupus erythematosus |
| 16803 |
| NF-kappa β signaling pathway; Toll-like receptor signaling pathway; Salmonella infection; Tuberculosis | 12124 |
| |
| 18534 |
| Citrate cycle; glycolysis; pyruvate metabolism; PI3K-Akt signaling pathway; insulin signaling pathway; AMPK signaling pathway; glucagon signaling pathway; PPAR signaling pathway; FoxO signaling pathway; adipocytokine signaling pathway | 223337 |
| |
| 171281 |
| Fatty acid elongation; biosynthesis of unsaturated fatty acids | 77864 |
| |
| 404634 |
| 105171 |
| ||
| 14219 |
| 226250 |
| ||
| 16598 |
| FoxO signaling pathway | |||
| 58158 |
| ||||
| 17748 |
| ||||
| 27410 |
| ||||
| 54484 |
| ||||
| 20208 |
| ||||
| 20201 |
| ||||
| 18406 |
| ||||
| 100047134 |
| ||||
| 100039405 |
| ||||
| 16019 |
| ||||
| 16819 |
| ||||
| 20209 |
| ||||
| 16658 |
| ||||
| 13009 |
| ||||
| 78934 |
| ||||
| 67876 |
| ||||
The expression value difference of the genes in N, H-1, and M-2 group should be more than 100 and two-fold change compared with C group.
National Center for Biotechnology Information (NCBI) Entrez Gene.
Co-expression of down-regulated genes and up-regulated genes in brain tissues
| Down-regulated genes | Up-regulated genes | ||||
|---|---|---|---|---|---|
| Gene ID | Gene symbol | Related pathways | Gene ID | Gene symbol | Related pathways |
| 70316 |
| Alzheimer disease; Parkinson disease; Huntington disease | 19378 |
| |
| 17772 |
| Inositol phosphate metabolism; phosphatidylinositol signaling system | 57357 |
| Steroid hormone synthesis |
| 22190 |
| PPAR signaling pathway | 16002 |
| MAPK signaling pathway; PI3K-Akt signaling pathway |
| 19212 |
| 100039008 |
| ||
| 66259 |
| 93880 |
| ||
| 11657 |
| ||||
| 270162 |
| ||||
| 18005 |
| ||||
The expression value difference of the genes in N, H-1, and M-2 group should be more than 100 and two-fold change compared with C group.
National Center for Biotechnology Information (NCBI) Entrez Gene.
Fig. 3The RNA relative expression levels of down-regulated (A) and up-regulated genes (B). Compared with C group, **P < 0.01.